TGTX TG Therapeutics Inc.

6.9
-0.1  -1%
Previous Close 7
Open 6.98
Price To Book 32.86
Market Cap 626763770
Shares 90,835,329
Volume 1,387,795
Short Ratio
Av. Daily Volume 2,006,127

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced November 27, 2017.
TGR-1202 (umbralisib) plus obinutuzumab
Relapsing or refractory Follicular Lymphoma
Phase 2a final data to be presented October 11, 2018. Annualized Relapse Rate (ARR) of 0.07.
TG-1101 (ublituximab)
Relapsing forms of Multiple Sclerosis (RMS)
Phase 3 completion of enrollment announced August 7, 2018. Data due mid-2020.
TG-1101 - ULTIMATE II
Multiple Sclerosis
Phase 1/2 poster at ASH 2017 showed 78% (7 of 9) ORR.
Umbralisib (TGR-1202) + Pembrolizumab + Ublituximab (TG-1101)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 completion of enrollment announced August 7, 2018. Data due mid-2020.
TG-1101 - ULTIMATE I
Multiple Sclerosis
Phase 2/3 MZL cohort met ORR primary endpoint. Data to be presented June 4, 2019, 11:45AM CT.
TG-1101 and TGR-1202 - UNITY-NHL study
Non-Hodgkin Lymphoma (NHL)
Phase 3 trial met primary endpoint - March 6, 2017. Data presented at ASCO 2017.
TG-1101 and IMBRUVICA (GENUINE trial)
Chronic Lymphocytic Leukemia (CLL) cancer
Phase 3 PFS data possibly due 2019.
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
Phase 1 updated data released at EHA June 2018. 2 patients (9%) achieved a durable complete remission.
TGR-1202
Myelofibrosis
Phase 1 trial initiation announced February 26, 2019.
TG-1801
Relapsed or Refractory B-cell Lymphoma

Latest News

  1. Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT
  2. TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
  3. TG Therapeutics Inc (TGTX) Q1 2019 Earnings Call Transcript
  4. TG Therapeutics: 1Q Earnings Snapshot
  5. TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
  6. TG Therapeutics to Host Conference Call on First Quarter 2019 Financial Results and Business Update
  7. TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting
  8. Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?
  9. Is TG Therapeutics a Buy?
  10. Did TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Sell Shares?
  11. TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma
  12. 5 Oncology Companies That Are Set to Run
  13. 3 Top Biotech Stocks to Buy in April
  14. Company News For Apr 2, 2019
  15. TG Therapeutics Breaks Out on Positive Umbralisib Data
  16. Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
  17. TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
  18. TG Therapeutics to Present Interim Data from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the Upcoming 2019 AACR Annual Meeting
  19. TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting
  20. What Makes TG Therapeutics (TGTX) a New Strong Buy Stock